X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (215) 215
Patent (23) 23
Publication (20) 20
Book / eBook (5) 5
Book Chapter (4) 4
Book Review (4) 4
Video Recording (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (96) 96
female (84) 84
adult (68) 68
middle aged (67) 67
oncology (63) 63
aged (51) 51
index medicus (51) 51
breast cancer (45) 45
breast neoplasms - drug therapy (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
chemotherapy (32) 32
breast neoplasms - pathology (29) 29
cancer (29) 29
male (29) 29
prognosis (25) 25
life sciences (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
chemistry (21) 21
therapy (21) 21
treatment outcome (21) 21
adhesives (20) 20
chemical paint or ink removers (20) 20
chemotherapy, adjuvant (20) 20
coating compositions, e.g. paints, varnishes orlacquers (20) 20
compositions based thereon (20) 20
compositions of macromolecular compounds (20) 20
correcting fluids (20) 20
disease-free survival (20) 20
dyes (20) 20
filling pastes (20) 20
inks (20) 20
metallurgy (20) 20
miscellaneous applications of materials (20) 20
miscellaneous compositions (20) 20
natural resins (20) 20
organic macromolecular compounds (20) 20
paints (20) 20
pastes or solids for colouring or printing (20) 20
polishes (20) 20
survival (20) 20
their preparation or chemical working-up (20) 20
use of materials therefor (20) 20
woodstains (20) 20
follow-up studies (19) 19
breast neoplasms - mortality (18) 18
materials for miscellaneous applications, not provided forelsewhere (17) 17
risk factors (17) 17
breast neoplasms - surgery (16) 16
care and treatment (16) 16
antineoplastic combined chemotherapy protocols - administration & dosage (15) 15
cyclophosphamide - administration & dosage (15) 15
prospective studies (15) 15
analysis (14) 14
cyclophosphamide (13) 13
drug administration schedule (13) 13
epirubicin - administration & dosage (13) 13
hematology, oncology and palliative medicine (13) 13
lymphatic metastasis (13) 13
women (13) 13
adhesive processes not provided for elsewhere (12) 12
fluorouracil - administration & dosage (12) 12
non-mechanical aspects of adhesive processes in general (12) 12
survival analysis (12) 12
tumors (12) 12
use of materials as adhesives (12) 12
france (11) 11
medicine & public health (11) 11
retrospective studies (11) 11
trastuzumab (11) 11
use of inorganic or non-macromolecular organic substances ascompounding ingredients (11) 11
young adult (11) 11
adjuvant chemotherapy (10) 10
aged, 80 and over (10) 10
breast neoplasms - genetics (10) 10
case-control studies (10) 10
clinical trials (10) 10
epirubicin (10) 10
neoplasm staging (10) 10
survival rate (10) 10
adolescent (9) 9
confidence intervals (9) 9
cyclophosphamide - adverse effects (9) 9
follow-up (9) 9
france - epidemiology (9) 9
metastasis (9) 9
neoplasm metastasis (9) 9
patients (9) 9
antimitotic agents (8) 8
antineoplastic agents (8) 8
antineoplastic agents - therapeutic use (8) 8
cancer therapies (8) 8
carcinoma (8) 8
epirubicin - adverse effects (8) 8
kaplan-meier estimate (8) 8
phase-ii trial (8) 8
pregnancy (8) 8
research (8) 8
adjuvant treatment (7) 7
breast neoplasms - metabolism (7) 7
clinical neurology (7) 7
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (189) 189
French (69) 69
German (4) 4
Spanish (4) 4
Danish (2) 2
Polish (2) 2
Slovenian (2) 2
Turkish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1442 - 1450
Summary Background Poor prognosis germ-cell tumours are only cured in about half of patients. We aimed to assess whether treatment intensification based on an... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST CYCLE | ETOPOSIDE | THERAPY | SOUTHWEST-ONCOLOGY-GROUP | CISPLATIN | ONCOLOGY | DENSE CHEMOTHERAPY | HIGH-DOSE CHEMOTHERAPY | COMPLETE-RESPONSE | CANCER | Testicular Neoplasms - mortality | Prognosis | Follow-Up Studies | Peritoneal Neoplasms - blood | Humans | Middle Aged | Male | Mediastinal Neoplasms - mortality | Neoplasms, Germ Cell and Embryonal - blood | Testicular Neoplasms - pathology | Cisplatin - administration & dosage | Young Adult | Mediastinal Neoplasms - drug therapy | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Peritoneal Neoplasms - drug therapy | Oxaliplatin | Chorionic Gonadotropin - blood | Adult | Female | Neoplasms, Germ Cell and Embryonal - drug therapy | Paclitaxel - administration & dosage | Precision Medicine | alpha-Fetoproteins - metabolism | Peritoneal Neoplasms - pathology | Lenograstim | Mediastinal Neoplasms - blood | Neoplasms, Germ Cell and Embryonal - mortality | Etoposide - administration & dosage | Survival Rate | Bleomycin - administration & dosage | Peritoneal Neoplasms - mortality | Recombinant Proteins - administration & dosage | Biomarkers, Tumor - blood | Ifosfamide - administration & dosage | International Agencies | Testicular Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Adolescent | Aged | Neoplasm Staging | Testicular Neoplasms - blood | Neoplasms, Germ Cell and Embryonal - pathology | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Tumors | Cancer | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 741 - 748
Summary Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer.... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | FOLLOW-UP | CHEMOTHERAPY | Breast Neoplasms - surgery | Predictive Value of Tests | Breast Neoplasms - secondary | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasms, Second Primary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | France | Heart Diseases - chemically induced | Radiotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Early Detection of Cancer | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Antimitotic agents | Care and treatment | Clinical trials | Breast cancer | Product development | Antineoplastic agents | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1493 - 1502
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1717 - 1725
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2004, Volume 22, Issue 15, pp. 3070 - 3079
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2006, Volume 24, Issue 36, pp. 5664 - 5671
Journal Article
by Garcia-Closas, Montserrat and Couch, Fergus J and Lindstrom, Sara and Michailidou, Kyriaki and Schmidt, Marjanka K and Brook, Mark N and Orr, Nick and Rhie, Suhn Kyong and Riboli, Elio and Feigelson, Heather S and Le Marchand, Loic and Buring, Julie E and Eccles, Diana and Miron, Penelope and Fasching, Peter A and Brauch, Hiltrud and Chang-Claude, Jenny and Carpenter, Jane and Godwin, Anew K and Nevanlinna, Heli and Giles, Graham G and Cox, Angela and Hopper, John L and Bolla, Manjeet K and Wang, Qin and Dennis, Joe and Dicks, Ed and Howat, Will J and Schoof, Nils and Bojesen, Stig E and Lambrechts, Diether and Broeks, Annegien and Anulis, Irene L and Guénel, Pascal and Burwinkel, Barbara and Sawyer, Elinor J and Hollestelle, Antoinette and Fletcher, Olivia and Winqvist, Robert and Brenner, Hermann and Mannermaa, Arto and Hamann, Ute and Meindl, Alfons and Lindblom, Annika and Zheng, Wei and Devillee, Peter and Goldberg, Mark S and Lubinski, Jan and Kristensen, Vessela and Swerdlow, Anthony and Anton-Culver, Hoda and Dörk, Thilo and Muir, Kenneth and Matsuo, Keitaro and Wu, Anna H and Radice, Paolo and teo, Soo Hwang and Shu, Xiao-Ou and Blot, William and Kang, Daehee and Hartman, Mikael and Sangrajrang, Suleeporn and Shen, Chen-Yang and Southey, Melissa C and Park, Daniel J and Hammet, Fleur and Stone, Jennifer and Veer, Laura J. Van't and Rutgers, Emiel J and Lophatananon, Artitaya and Stewart-Brown, Sarah and Siriwanarangsan, Pornthep and Peto, Julian and Schrauder, Michael G and Ekici, Arif B and Beckmann, Matthias W and dos Santos Silva, Isabel and Johnson, Nichola and Warren, Helen and Tomlinson, Ian and Kerin, Michael J and Miller, Nicola and Marme, Federick and Schneeweiss, Aneas and Sohn, Christof and Truong, Therese and Laurent-Puig, Pierre and Kerbrat, Pierre and Nordestgaard, Børge G and Nielsen, Sune F and Flyger, Henrik and Milne, Roger L and Perez, Jose Ignacio Arias and Menéndez, Primitiva and Müller, Heiko and Arndt, Volker and Stegmaier, Christa and Lichtner, Peter and Lochmann, Magdalena and Justenhoven, Christina and ... and KConFab Investigators and Gene ENvironm Interaction Breast and Familial Breast Canc Study FBCS and Australian Breast Canc Tissue Bank and kConFab Investigators and Familial Breast Cancer Study (FBCS) and Australian Breast Cancer Tissue Bank (ABCTB) Investigators and Gene ENvironmental Interaction and breast CAncer (GENICA) Network and The Gene ENvironmental Interaction and breast CAncer (GENICA) Network
Nature genetics, ISSN 1061-4036, 2013, Volume 45, Issue 4, pp. 392 - 398
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2003, Volume 21, Issue 2, pp. 298 - 305
Journal Article